^
Association details:
| Biomarker: | PTGR1 elevation + HRD |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | hydroxyureamethylacylfulvene (STAR-001) (Alkylating agent) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synthetic lethality of LP-184, a next generation acylfulvene, in ex vivo PDX models with homologous recombination defects
Published date:
05/19/2021
Excerpt:
We evaluated ex vivo antitumor activity of LP-184 in selected PDX models representing lung, pancreatic and prostate cancers with high PTGR1 and known HR defects. 17.6% of lung adenocarcinomas (n = 517), 4.5% of pancreatic adenocarcinomas (n = 179) and 9.6% of prostate adenocarcinomas (n = 498) displayed elevated PTGR1 along with damaging HR related mutations, and are likely to be responsive to LP-184 based on analysis of TCGA data.
DOI:
10.1200/JCO.2021.39.15_suppl.e15064
